Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade

Executive Summary

Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion
Advertisement

Related Content

Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
Shionogi Buys Sciele: U.S. Sales Platform For Crestor Innovator
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Takeda/ Millennium: The Price is Right
Takeda buys Abbott’s stake in TAP
Advertisement
UsernamePublicRestriction

Register

PS049517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel